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Abstract: Bariatric surgery is an effective intervention for management of obesity through treating
dysregulated appetite and achieving long-term weight loss maintenance. Moreover, significant
changes in glucose homeostasis are observed after bariatric surgery including, in some cases, type 2
diabetes remission from the early postoperative period and postprandial hypoglycaemia. Levels of a
number of gut hormones are dramatically increased from the early period after Roux-en-Y gastric
bypass and sleeve gastrectomy—the two most commonly performed bariatric procedures—and
they have been suggested as important mediators of the observed changes in eating behaviour
and glucose homeostasis postoperatively. In this review, we summarise the current evidence from
human studies on the alterations of gut hormones after bariatric surgery and their impact on clinical
outcomes postoperatively. Studies which assess the role of gut hormones after bariatric surgery on
food intake, hunger, satiety and glucose homeostasis through octreotide use (a non-specific inhibitor
of gut hormone secretion) as well as with exendin 9–39 (a specific glucagon-like peptide-1 receptor
antagonist) are reviewed. The potential use of gut hormones as biomarkers of successful outcomes of
bariatric surgery is also evaluated.
Keywords: gut hormones; bariatric surgery; GLP-1; PYY; ghrelin; Roux-en-Y gastric bypass; gastric
band; sleeve gastrectomy
1. Introduction
Obesity is a complex, chronic, progressive and relapsing disease which affects cur-
rently approximately 650 million adults worldwide [1,2]. Complications of obesity include
type 2 diabetes mellitus (T2D), cancer, sleep apnoea, cardiovascular, musculoskeletal, re-
productive and psychological morbidities [3]. The cornerstone of prevention and treatment
of obesity is behavioural changes together with diet and exercise (lifestyle changes) [4].
However, lifestyle approaches for treatment of severe obesity and its associated compli-
cations often do not achieve enough weight loss to reverse complications and weight
loss maintenance remains a major challenge [5–7]. Current available pharmacotherapy in
combination with the lifestyle changes can add a further weight loss of 2.6–8.8% [8] and
help with weight maintenance [7,9], but newer medications promise more weight loss in
the long term [10,11]. Even so, bariatric surgery remains a valuable tool for weight loss,
leading to improvements in health, functionality and quality of life [12–15], especially for
those that lifestyle- and medication-based approaches have proven ineffective to achieve
and maintain clinically significant weight loss.
Currently, around 685,000 weight loss operations are performed every year world-
wide [16] and the three most commonly performed procedures are the Roux-en-Y gastric
bypass (RYGB), the sleeve gastrectomy (SG) and the adjustable gastric band (AGB) [16,17].
Bariatric surgery achieves successful weight loss and weight maintenance long-term
as a result of reduced caloric intake postoperatively due to decreased hunger and increased
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satiety [18–22]. The changes in satiety are profound from the early postoperative period
after RYGB and SG and, in some cases, there are also alterations in food preferences after
these procedures [23,24]. These findings are different to what is observed after low-calorie
diet, which can be very effective in the induction of weight loss, however, the vast majority
of people fail to maintain the achieved weight loss in the long-term [6,7,25,26]. On a
low-calorie diet, people usually report an increase in hunger, a decrease in satiety and an
increased desire to eat [18,27,28] and this is likely due to robust compensatory processes
that resist a drift of body fat stores below an established “set point” [29,30]. The alterations
in gut hormone levels after diet-induced weight loss have been suggested as an important
mediator of eating behaviours favouring weight regain in the long term [27,31]. More
specifically, ghrelin, a hunger hormone, is increased after diet-induced weight loss when
postprandial levels of satiety hormones are decreased [27,31].
In contrast, RYGB and SG lead to increased postprandial secretion of satiety hor-
mones including glucagon-like peptide-1 (GLP-1), peptide YY (PYY), and oxyntomodulin
(OXM) [23,32–34]. These changes in gut hormone secretion from the early period after
RYGB and SG have been suggested as potential mediators of the increased satiety and
reduced hunger postoperatively, indicating that bariatric surgery may address the dys-
functional appetite regulation in people with obesity. Moreover, significant improvements
in glucose homeostasis and even remission of T2D occurs within days after bariatric
surgery [35–37] due to well described changes in insulin secretion and sensitivity from the
early postoperative period [38–40]. The known effect of GLP-1 on insulin secretion [41,42]
combined with the elevated GLP-1 levels postoperatively further increases the interest
about the gut hormones as potential mediators of these effects.
In this review, we will evaluate the currently available evidence from human studies on:
(a) The changes in gut hormones after bariatric surgery (Section 2);
(b) The role of gut hormones on weight loss outcomes after bariatric surgery (Section 3)—
more specifically we will review their role as (i) biomarkers of successful weight
loss postoperatively (Sections 3.1 and 3.2) and as (ii) mediators of the postoperative
changes in food intake and appetite (Section 3.3);
(c) The role of GLP-1 after bariatric surgery on glycaemic outcomes (Section 4)—we will evalu-
ate the role of GLP-1 as mediator (i) of type 2 diabetes improvement/remission (Section 4.1)
and (ii) of postprandial hyperinsulinaemic hypoglycaemia (PHH) (Section 4.2).
Figure 1 demonstrates the three main sections of this review article for convenience
of the readers. The focus for the sections exploring the role of gut hormones as mediators
of weight loss and glycaemic outcomes after bariatric surgery will be on studies using
either octreotide (a nonspecific inhibitor of gut hormones secretion) or exendin 9–39 (Ex-9,
a specific GLP-1 antagonist).
2. Changes in Gut Hormones after Bariatric Surgery
Changes in gut hormone levels—especially those secreted from the L-cells with highest
density in the ileum (such as GLP-1, PYY, OXM and glicentin)—have been consistently
seen from the early postoperative period after RYGB and SG (Table 1). In contrast, gut
hormone levels do not significantly change after AGB (Table 1).
2.1. Potential Explanations for the Increased Postprandial Gut Hormone Secretion from the Distal
Gut after RYGB and SG
In people with severe obesity, gastric emptying and small intestinal transit time are
slower compared to lean people and are associated with reduction in postprandial glucose
absorption and glycaemic excursions as well as with reduced postprandial rise in GLP-1
and glucose-dependent insulinotropic polypetide levels (GIP) [43].
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Figure 1. Structure of the review article.
After RYGB, the rapid gastric emptying of both solids and liquids [44–47] and the by-
pass of the stomach and duodenum postoperatively result in accelerated nutrient delivery
and absorption to the distal part of the gut [45] and subsequently to increased postprandial
secretion of gut hormones [33,45,48,49]. After SG, there is increased gastric pressure [50,51],
accelerated gastric emptying of nutrients [45,52,53] and accelerated small bowel transit [54]
to induce an early and prolonged secretion of L-cell hormones from the intestine. In con-
trast, AGB does not alter the rate of gastric emptying for solids or liquids [55,56] and this
is probably the reason that gut hormone secretion from the distal part of the gut is not
significantly altered post-AGB [56].
There are differences between RYGB and SG on macronutrient absorption—glucose
and protein absorption are accelerated after RYGB [57,58], when after SG glucose absorption
is increased (but less compared to RYGB) and protein absorption is not modified [45]. These
differences may account for the different hormonal profiles observed between the two
procedures [34,45].
The nutrient absorption from the gut appears to be more important for the gut hor-
mone secretion compared to the exposure of the gut to nutrients [59,60]. Further evidence
on the importance of glucose absorption on GLP-1 secretion after RYGB comes from a study
where sodium glucose co-transporters-1 (SGLT-1), a major mechanism of dietary glucose
absorption from the gastrointestinal tract, were blocked in people who have undergone
RYGB through canagliflozin, a dual SGLT-1/SGLT-2 inhibitor [61]. The study found that
indeed dual SGLT-1/SGLT-2 inhibition could reduce glucose absorption and subsequently
reduce peak GLP-1 levels and insulin secretion after RYGB [61].
High gastric emptying rates after RYGB for prolonged periods may also induce adap-
tive changes, such as an increase in enteroendocrine cell number and surface area [62,63].
Experiments with gastrostomy feeding and reversal of RYGB demonstrate acute rever-
sal of excessive gut hormone secretion immediately after rerouting of nutrients to the
stomach or after reversal of RYGB [64,65]. This supports the concept that the rapid de-
livery and absorption of the nutrients at the distal part of the gut constitutes a more
potent stimulus for secretion of gut hormones after RYGB compared to the changes in the
enteroendocrine cells.
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Other mechanisms, such as changes in bile acid flow and bile acid plasma levels,
may also play a role in gut hormone secretion after bariatric surgery, especially after
RYGB [66–68]. However, further studies are required to define the role of bile acids on gut
hormone secretion after bariatric surgery, particularly as evidence on changes of bile acid
levels after SG is conflicting [69–73] and the time course of bile acid changes after RYGB is
unclear [70,72–74].
2.2. Ghrelin
Ghrelin is mainly produced from the X/A like cells of the stomach and to a lesser
degree from the small intestine. Ghrelin is considered to be most active in its acylated
form, and is a known orexigenic hormone which stimulates appetite and food intake [75].
Furthermore, ghrelin inhibits insulin secretion in healthy people [75–77]. Plasma ghrelin
levels are typically increased during prolonged fasting and suppressed immediately after
food intake [75,78,79]. In states of increased adiposity, lower fasting plasma ghrelin levels
are observed, coupled with blunted postprandial ghrelin suppression [80,81].
Changes in ghrelin levels after bariatric surgery are presented in Table 1 [33,34,82–94].
It is of note that during the first months after RYGB, fasting and postprandial ghrelin levels
are decreased, but over the first postoperative year, ghrelin levels after RYGB gradually
increase [34,86–90].
2.3. GIP
GIP is secreted from K cells found throughout the small intestine, but in highest
proportion in the duodenum and jejunum. GIP increases insulin secretion following
ingestion of oral glucose in healthy volunteers [41]. On the other hand, in people with T2D,
the insulinotropic capacity of exogenous GIP is markedly attenuated, but it appears to be
improved after near-normalisation of glycaemic control [41,95,96].
The changes in postprandial levels of GIP after RYGB and SG are inconsis-
tent [33,48,83,97–101] (Table 1). On the other hand, GIP levels after AGB appear un-
changed [33,56,102–104] (Table 1).
2.4. GLP-1
Glucagon-like peptide 1 (GLP-1) is secreted from L cells which predominate in the
distal ileum and colon. GLP-1 stimulates insulin release in response to nutrient ingestion
and reduces blood glucose levels in a glucose-dependent manner [41,105]. GLP-1 is rapidly
inactivated by the enzyme dipeptidyl-peptidase-4 (DPP-4) [106]. Additionally, endogenous
GLP-1 inhibits gastric emptying, inhibits glucagon secretion and has centrally mediated
effects upon appetite [105,107].
Postprandial levels of GLP-1 are significantly elevated after RYGB and
SG [32–34,45,83,85,90], but they remain stable after AGB [56,89,91,94] (Table 1). The in-
crease in postprandial GLP-1 levels after RYGB is more profound compared to SG in some
studies [34,45], but not in all [90,108].
2.5. PYY
PYY is a peptide secreted from intestinal endocrine L-cells of the distal gut following
food ingestion along with GLP-1 [82,109]. Following cleavage in the circulation by the
enzyme DPP-4, PYY 1–36 is converted to PYY 3–36 which is considered to promote sati-
ety [81]. PYY is released postprandially in proportion to the calories ingested [110] and it
increases satiety, reduces food intake, delays gastric emptying and reduces postprandial
insulin secretion [111–113].
Alterations in PYY levels after bariatric surgery [21,32,34,45,83,85,89,91,94,108,114]
are described in Table 1. Postprandial PYY levels are elevated after RYGB and SG, with
more potent changes after RYGB [34,91,108,114].
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2.6. Oxyntomodulin
Oxyntomodulin (OXM) is a peptide hormone which is structurally similar to glucagon
and is produced by the L-cells of the gut [81,115]. OXM is a weak dual agonist of GLP-1
receptor and glucagon receptor [116]. A specific receptor for mediating the effect of OXM
has not yet been identified in humans. Exogenous administration of OXM reduces food
intake and increases energy expenditure in humans [117,118]. Few studies have assessed
the changes in oxyntomodulin levels after bariatric surgery [23,33,97,119] and their results
are presented in Table 1.
2.7. Glicentin
Glicentin contains the entire sequences of oxyntomodulin (and hence glucagon) and
glicentin-related pancreatic peptide [120] and it is cleaved from the proglucagon prohor-
mone in the L-cell. It is unclear whether glicentin is a metabolically inert by-product
of proglucagon processing, which is co-secreted from the L-cell, or has a distinct func-
tion [120,121]. Currently, there is no known glicentin receptor in humans. Limited data is
also available on the changes of glicentin levels after bariatric surgery [23,33,97], however
postprandial glicentin levels appear to be elevated after RYGB (Table 1).
3. The Role of Gut Hormones on Weight Outcomes after Bariatric Surgery
3.1. Gut Hormone Levels as Predictors of Weight Loss before and after Bariatric Surgery
Werling et al. [122] reported that preoperative responses of GLP-1 and PYY to a mixed
meal do not correlate with postoperative weight loss after RYGB surgery.
After RYGB and SG, the postprandial increase in oxyntomodulin and glicentin levels
[% change of Area Under the Curve (AUC)]) during the first three to six months predict
successful weight loss at twelve to eighteen months postoperatively [23,33] and it was
also associated with favourable changes in eating behaviour [23]. The increase in glicentin
levels was the strongest hormonal predictor of weight loss (was able to explain 22% of
variation in weight loss at eighteen months [23]), but combining multiple gut hormones
(including PYY, ghrelin, GLP-1, oxyntomodulin and glicentin) not surprisingly increased
further the predictive power for postoperative weight loss, suggesting synergistic effects
of gut hormones for weight loss after bariatric surgery [23]. These results may reflect that
glicentin, because of its longer half-life, is probably the best marker for the secretion of
proglucagon-derived hormones with already established effects on food intake and weight
loss (such as GLP-1) rather than being indicative of a regulatory role for glicentin on food
choice and weight loss [23]. Therefore, early postprandial responses of gut hormones,
including glicentin, may be early markers of postoperative weight loss.
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Table 1. Changes in gut hormones after the most commonly performed bariatric procedures.
H RYGB SG AGB














Postprandial ↓ [33,103] or↔ [48,97,101]
or ↑ [98,101]
Fasting↔ [33,83,104]




















Postprandial↔ [23] or ↑ [33]
Fasting↔ [33]
Postprandial NA
Glicentin Fasting↔ [33,97] or ↑ [23]
Postprandial ↑↑ [23,33,97]
Fasting↔ [23] or ↑ [33]
Postprandial↔ [23] or ↑ [33]
Fasting↔ [33]
Postprandial NA
RYGB: Roux-en-y gastric bypass, SG: Sleeve gastrectomy, AGB: Adjustable gastric band, GLP-1: Glucagon Like Peptide-1, PYY: Peptide YY, GIP: Glucose-dependent Insulinotropic Polypeptide, OXM:
Oxyntomodulin, ↓ reduced compared to preoperatively,↔ no change compared to preoperatively, ↑ increased compared to preoperatively, ↓↓ very reduced compared to preoperatively, ↑↑ very increased
compared to preoperatively, NA: limited/no data available. Referenced studies are presented in brackets.
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3.2. Gut Hormone Levels in Poor and Good Responders after Bariatric Surgery
As discussed, multiple satiety gut hormones are elevated after RYGB and SG, but is
there a difference in gut hormone levels between “good” responders and “poor” responders
to bariatric surgery? Almost all the studies which have addressed this question have been
performed after RYGB. Despite the different definitions for “good” and “poor” responders
between the studies, people with “poor” postoperative weight loss after RYGB have
elevated ghrelin levels and reduced secretion of satiety gut hormones (mainly GLP-1 levels
and in some cases PYY levels) compared to “good” responders to the operation [19,123–125].
Moreover, suppression of hunger was more pronounced in “good” responders to RYGB
after a standardized meal compared to “poor” responders [19,125].
“Poor” responders to bariatric surgery can be further categorized as primary “poor”
responders (people who have undergone bariatric surgery and achieved suboptimal maxi-
mum weight loss compared to the expected) and secondary “poor” responders (people
who achieved good maximum weight loss, but then experienced significant weight regain).
There is a lack of standardisation in definitions for primary and secondary “poor” respon-
ders and “good” responders [126,127]. The majority of people who are “poor” responders
to bariatric surgery are secondary “poor” responders, with a 5% of bariatric surgery pop-
ulation being primary “poor” responders [126]. There may be a number of differences
in physiology between primary and secondary “poor” responders compared to “good”
responders to bariatric surgery.
De Hollanda et al. [124] evaluated whether there is a difference in gut hormones
between people who are secondary “poor” responders to RYGB (n = 22) compared to
“good” responders to RYGB (n = 32). They reported that secondary “poor” responders
have lower GLP-1 and PYY levels and less suppression of ghrelin following a mixed meal
test than “good” responders. Furthermore, ad libitum food intake (both absolute and body
weight adjusted food intake) was increased in secondary “poor” responders compared to
“good” responders to RYGB.
The main limitation in studies investigating differences between “good” and “poor”
responders after bariatric surgery is the cross-sectional design. Thus, it is not possible
to know whether the observed differences in gut hormones between “good” and “poor”
responders were actually preceded the weight loss/weight gain postoperatively or are
merely a consequence of the difference in body weight at the time of the study.
3.3. Gut Hormones and Their Role in Appetite and Food Intake after Bariatric Surgery
The increased levels of postprandial secretion of gut hormones (GLP-1, PYY) and their
known role in food intake and appetite have predictably led to the hypothesis that changes
in gut hormones are contributed to the observed changes in appetite and food intake after
RYGB and SG. To demonstrate causality for the effect of gut hormones on satiety and
food intake after bariatric surgery, a somatostatin analogue (octreotide) has been used
to non-specifically attenuate the response of postprandial gut hormones (Table 2). The
first evidence to strongly suggest a role for the exaggerated response of gut hormones
was provided when increased food intake and reduced satiety was shown in patients
after RYGB who received octreotide compared to saline (placebo) within a randomized
controlled trial [19]. In contrast, patients who had undergone AGB (an operation with
minimal effect on gut hormones), did not exhibit changes in appetite or food intake with
octreotide administration [19].
De Hollanda et al. [124] also found that octreotide suppressed gut hormone secretion,
increased food intake and suppressed satiety after RYGB. However, the observed changes
in food intake and satiety were comparable in secondary “poor” responders and “good”
responders to RYGB, suggesting that the role of gut hormones in the weight regain in
secondary “poor” responders may be limited.
In a recently presented conference abstract, Bojsen-Moller et al. [128] reported that
in primary “poor” responders to RYGB, octreotide attenuates gut hormone secretion but
does not affect ad libitum food intake. In contrast, in “good” responders to the RYGB,
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there was an increase of 23% in ad libitum food intake with octreotide compared to
placebo. Interestingly, in this study there was no significant difference in postprandial gut
hormone levels (GLP-1, PYY or post-meal suppression of ghrelin) between primary “poor”
responders and “good” responders. These observations suggest that impaired regulation
of food intake by gut hormones may contribute to a primary “poor” response to RYGB.
As octreotide has non-specific effects to block gut hormone secretion, it is difficult
to identify the main gut hormones contributing to food intake and appetite changes after
RYGB. Moreover, octreotide has an inhibitory effect on gastrointestinal motility [129], which
may improve postprandial symptoms and affect further the appetite postoperatively.
In an attempt to isolate the particular role of GLP-1 on inhibition of food intake after
RYGB, Svane et al. [130] used the specific GLP-1 receptor antagonist Ex-9. Preoperatively,
Ex-9 was associated with a 35% increased food intake in patients with obesity and T2D prior
to RYGB compared to placebo. After RYGB, while food intake was less than preoperatively
during Ex-9 and saline administration, there was no difference in food intake between Ex-9
and placebo. However, after administration of Ex-9, the already elevated postoperative
GLP-1 and PYY levels were further increased. The increase in PYY levels was interpreted
to indicate that while an inhibitory effect of GLP-1 on food intake may have been removed
with the antagonist, at the same time an even greater PYY response occurs, which would
favour inhibition of food intake so that the influence of Ex-9 on food intake after RYGB is
neutral [130,131].
A subsequent study accordingly tried to block both GLP-1 and PYY actions [130]. Ex-9
was used to block GLP-1 actions, but as there is no available antagonist of PYY for use in
humans, a DPP-4 inhibitor was used in order to inhibit the conversion of PYY 1–36 to PYY
3–36, which appears to be the actual satiety-promoting form of the hormone. In a crossover
study patients after RYGB received placebo, Ex-9, sitagliptin (a DPP-4 inhibitor), and a
combination of Ex-9 and sitagliptin. GLP-1 and PYY 3–36 levels were increased during
placebo, and further increase following Ex-9 administration was observed as expected. The
DPP-4 inhibitor caused further increases in active GLP-1 levels, but almost abolished the
PYY 3–36 responses to food intake. The Ex-9 plus DPP-4 inhibitor in combination were
associated with a significant increase of 20% in food intake [130,131]. These observations
strongly support the concept that GLP-1 and PYY 3–36 are involved synergistically in the
inhibition of appetite and food intake following RYGB.
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Roux-en-Y gastric bypass, EWL%: Excess Weight Loss, EBLmax: Maximum Excess BMI Loss, F: Female, MMTT: Mixed Meal Tolerance Test, NR: Not Reported, ↑: increased with octreotide vs. placebo,↔: no
change with octreotide vs. placebo, ↓: reduced with octreotide vs. placebo,*: significant difference between study groups on the outcome change with octreotide vs. placebo, NC: no comparison performed
between study groups on the outcome change with octreotide vs. placebo, ND: no difference between study groups on the outcome change with octreotide vs. placebo.
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4. The Role of GLP-1 on Glycaemic Outcomes after Bariatric Surgery
4.1. GLP-1 as a Mediator of the Improvement in Glucose Homeostasis in People with Type 2
Diabetes after Bariatric Surgery
Yoshino et al. assessed the changes in glucose homeostasis before and after matched
weight loss induced by RYGB (n = 22) or diet alone (n = 22) in people with obesity and
T2D [132]. After 18% weight loss, they found similar improvements in insulin sensitivity
and beta cell function with RYGB and diet, suggesting that weight loss is the main driver
for the observed improvements in glycaemic parameters after RYGB [132]. However, after
bariatric surgery, the improvement in glucose homeostasis for people with T2D is observed
from the first postoperative days, supporting the existence of weight loss independent
mechanisms [36,133].
During the first postoperative weeks, the improvement in hepatic insulin sensitivity
and insulin clearance due to calorie restriction and reduction in liver fat are contributed
to the improvement in glucose homeostasis [36,39,134]. Additionally, the existence of
RYGB mechanisms relevant to improvement in postprandial glucose metabolism which are
independent to weight loss and calorie restriction is supported by the example of a patient
with insulin-treated T2D who had a gastrostomy tube inserted after RYGB [135]. Five
weeks after RYGB, this patient was given identical meals orally or through the gastrostomy
tube on 2 consecutive days. On the day of oral feeding (200 mL of liquid meal, 300 kcal,
consumed over 10 min), he had normal glucose tolerance with large GLP-1 and insulin
responses; on the day of gastrostomy feeding (same meal, given over 10 min), he had
glucose levels consistent with T2D and low GLP-1 and insulin levels. This was later
confirmed in a larger cohort of patients [65]. These observations suggest an effect of RYGB
on insulin secretion and beta cell function which can be activated by diverting food via the
duodenum and it is independent of weight loss and calorie restriction.
Indeed, immediately after RYGB, beta cell function in response to a meal improves in
subjects with T2D accompanied by an increased postprandial GLP-1 secretion [133,136–138].
Studies with Ex-9, have demonstrated causality between the increased GLP-1 secretion
and the increased postprandial insulin secretion after RYGB in people with T2D (Table 3).
In every study where people with T2D preoperatively were given Ex-9 vs. placebo after
RYGB, at any postoperative time point, postprandial insulin secretion (whether measured
as insulin, c-peptide or insulin secretion rate) was significantly reduced following Ex-9
administration and compared to the non-operated control population [37,139–141] (Table 3).
Similar findings have been reported in people with T2D remission two years after SG [142]
and in people without T2D who have undergone RYBG or SG [142–146]. These findings
confirm that postprandial GLP-1 action is key mediator of postprandial insulin secretion
after RYGB and SG; however, whether this increased insulin secretion is fundamental to
the improvement in postprandial glucose levels during the early postoperative period in
people with T2D is more complex, as multiple other factors may contribute to glucose
homeostasis. These factors include the improved hepatic insulin sensitivity and insulin
clearance due to caloric restriction during the first weeks postoperatively and, subsequently,
on the gradual improvement in peripheral insulin sensitivity due to weight loss [39,131].
4.1.1. Studies Using Exendin 9–39 during the Early Postoperative Period in People with
Type 2 Diabetes after Bariatric Surgery
Jorgensen et al. [37] studied meal-induced responses in patients with obesity and
T2D before, 1 week and 3 months after RYGB with or without simultaneous infusions of
Ex-9. The Ex-9 administration impaired insulin secretion before, and particularly after, the
operation; insulin secretion reverted to the preoperative values with the Ex-9 infusion at
the first week and the third month postoperatively. As a result, with the administration of
Ex-9 glucose tolerance worsened to preoperatively levels at the first week postoperative
and was still impaired at 3 months. These findings strongly support a role of GLP-1
for improved beta cell function and improvement in glucose tolerance during the first
postoperative weeks.
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Another study by Shah et al. [141] assessed the role of GLP-1 action on insulin secretion
and insulin clearance rate after an oral glucose tolerance test at 3 months post-RYGB, in
people with T2D preoperatively (n = 22). Blockade of GLP-1 action with Ex-9 resulted
as expected in 49% reduction in postprandial insulin levels and 51% reduction in insulin
secretion rate compared to placebo as well as in 19% increase in postprandial insulin
clearance rate [141]. However, this study did not have a non-surgical control group and
did not report the changes in glucose levels.
On the other hand, a prospective case–control study compared the effects of Ex-9
on insulin secretion and postprandial glucose levels in 10 people with T2D after RYGB
and 10 people with T2D who received an intensive lifestyle intervention after both groups
have achieved 10% weight loss (12 kg) [140]. As expected, despite the comparable weight
reduction between the two groups, RYGB was associated with a larger postprandial GLP-1
and insulin secretion compared to the intensive lifestyle intervention group. Ex-9 had a
greater impact on insulin secretion reduction in people who have undergone RYGB than
the intensive lifestyle group. Postprandial glucose levels and glucose tolerance deteriorated
comparably in both RYGB and intensive lifestyle modification group during Ex-9 infusion.
Therefore, this study confirms that in people with T2D preoperatively, GLP-1 action after
RYGB has an important role on postoperative insulin secretion. However, the role of the
excessive GLP-1 secretion after RYGB on the improvement of postprandial glucose levels
and glucose tolerance after 10% weight loss may be limited compared to other factors such
as the improved hepatic and peripheral insulin sensitivity, a finding in partial agreement
with the study from Yoshino et al. [132]
An important factor that may contribute to the attenuated improvement in postpran-
dial glucose levels after RYGB despite the substantial improvement in GLP-1 mediated
insulin secretion is the paradoxical increase in postprandial glucagon levels after RYGB
compared to the non-surgical groups, which increases further after administration of
Ex-9 [37,140,147]. The underlying aetiology for the increased glucagon levels after gastroin-
testinal surgery is still under investigation. The glucagon concentrations after RYGB appear
to follow closely the amino acid absorption and plasma amino acid concentrations [45], in
agreement with recent evidence suggesting that glucagon and amino acids are linked in
a mutual feedback cycle between the liver and the pancreatic a-cells [148]. Furthermore,
there is evidence that part of the excessive postprandial glucagon concentration after RYGB
might be gastrointestinally derived. More specifically, the expression of the glucagon gene
in the small intestine appears to be increased after surgery and glucagon was identified in
small intestine biopsy specimens obtained after, but not before RYGB [149]. These findings
suggest that glucagon derived from small intestine enteroendocrine L cells may contribute
to postprandial plasma concentrations of glucagon after RYGB [149]. Finally, accurate
measurement of postprandial glucagon levels after RYGB can be challenging [150] and
in some cases, the elevated plasma glucagon in people after gastrointestinal surgery may
represent an assay artefact due to increased concentrations of cross-reacting proglucagon
peptides [151].
Future research on the role of GLP-1 on T2D remission/improvement during the early
postoperative period may also focus in people who have undergone SG. Currently there is
limited number of studies with Ex-9 for people with T2D who have undergone SG (Table 3),
despite that it is the most commonly performed procedure worldwide.
4.1.2. Studies Using Exendin 9–39 after the Early Postoperative Period in People with Type
2 Diabetes after Bariatric Surgery
Few studies have investigated the effect of endogenous GLP-1 action on postprandial
glucose levels in subjects with T2D remission who had undergone RYGB or SG at least
two years before assessment, with the use of Ex-9 (Table 3) [139,142]. Jimenez et al. [139],
in a cross-sectional study, assessed eight people who had undergone RYGB and achieved
T2D remission and 34% weight loss at the time of assessment. A control group of seven
people without diabetes and normal BMI was also recruited. In the RYGB group, insulin
and C-peptide secretion decrease with Ex-9 administration, by 52% and 24%, respectively,
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when there was no change in insulin and C-peptide levels with Ex-9 administration in
the control group. Postprandial glucose levels in the RYGB group after administration
of Ex-9 increased by approximately 2 mmol/l between 90′ and 120′ post-meal which
was not observed in the control group [139]. This study accordingly confirmed a role of
GLP-1 for increased insulin secretion in people with T2D remission even >2 years after
RYGB. Moreover, it demonstrated that GLP-1 action is contributed to the improvements in
postprandial glucose levels for people who achieve T2D remission after RYGB, even if the
improvement in peripheral insulin sensitivity due to substantial weight loss appears to be
the main mediator of the improvement in postprandial glucose levels and T2D remission
at this time.
A subsequent study from the same group assessed eight people with obesity and T2D
who underwent SG more than two years ago and had achieved T2D remission. There was
a control group with six BMI-matched people without T2D preoperatively who have also
undergone SG at least 2 years ago and a second control group of eight people without
diabetes and normal BMI [142]. Ex-9 administration was associated with impaired insulin
secretion in the SG groups (the T2D remission group and the control group without
T2D) compared to the non-operated control group. The blockade of GLP-1 through Ex-9
resulted in a moderate deterioration of postprandial glucose levels in all the three groups.
However, postprandial glucose levels after Ex-9 were comparable between the three groups
suggesting a limited role for the excess GLP-1 secretion after SG on the improvement in
postprandial glucose levels in people with T2D remission after significant weight loss
through SG.
An important consideration to the above studies using Ex-9 to investigate the role
of GLP-1 on insulin secretion and postprandial glucose levels in people with T2D after
bariatric surgery is that almost all of them have been performed in people with short dura-
tion of T2D and presumably reasonable beta cell functional capacity [37,139,140,142]. Peo-
ple with impaired insulin secretion and beta cell function before and after surgery are those
who do not achieve T2D remission [137,152], despite that postprandial GLP-1 levels are
similar between people who achieve or do not achieve T2D remission [37,139,140,142,153].
Therefore, exaggerated GLP-1 responses after RYGB and SG are probably insufficient in
individuals with poor functional capacity of beta cells to secrete enough insulin and to
achieve important improvement in postprandial glucose levels postoperatively [153,154].
Another limitation of studies assessing the impact of Ex-9 on glucose homeostasis
after bariatric surgery is the small number of participants (the majority of studies had less
than 10 participants, Table 3) and therefore the results should be interpreted with caution.
Other challenges regarding the interpretation of the results include the different amount
of intravenous Ex-9 administered at different studies (Table 3), as well as the increased
glucagon levels after Ex-9 administration in some cases [155], which as discussed before,
may affect the postprandial glucose levels. Finally, the increased levels of PYY and GLP-1
after Ex-9 administration [130] may suggest that Ex-9 interfere with intestinal endocrine
feedback loops [155] which may also affect the glucose levels.
Between the other gut hormones (except of GLP-1) which may contribute to changes
in glucose homeostasis after bariatric surgery, GIP is of interest due to its known in-
sulinotropic effect. Data on GIP action after bariatric surgery is limited and GIP levels
are inconsistent after RYGB and SG. There are no studies with specific GIP antagonists to
assess the role of GIP on glucose homeostasis after RYGB or SG. To determine whether GIP
is important after RYGB, patients without diabetes who underwent RYGB were given the
DPP-4 inhibitor sitagliptin to increase the bioavailability of both GLP-1 and GIP [146,156].
They then received Ex-9 (in combination with sitagliptin) in order to block GLP-1 action
and consequently, isolate the impact of GIP signalling on glucose tolerance. Interestingly,
sitagliptin did not improve glucose tolerance or beta cell function when GLP-1 receptor sig-
nalling was blocked [146]. In contrast, patients with T2D who have not undergone bariatric
procedures fully responded to the DPP-4 inhibitor with improved glucose tolerance and
insulin secretion, when DPP-4 inhibitor was combined with Ex-9 [156,157]. Together these
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data may suggest that RYGB shifts the balance of the incretin effect towards GLP-1 and
away from GIP [156]. Nevertheless, a specific GIP antagonist for human use is currently
available and its use in future studies may help us understand better the role of GIP as
well as the role of the combined GIP/GLP-1 action on glucose homeostasis and diabetes
remission after bariatric surgery [155].
4.2. GLP-1 and Postprandial Hypoglycaemia after Bariatric Surgery
Postprandial hyperinsulinaemic hypoglycaemia (PHH) is a well described condition
after RYGB and SG, which is associated with reduced quality of life, high degree of func-
tional disability (inability to work, drive and care for others) and weight regain [158–160].
The incidence of PHH ranges between 17–75% after RYGB and SG, depending on the
definition of hypoglycaemia, the population studied and the diagnostic tool used to assess
hypoglycaemia [161–168]. The vast majority (around 80%) of hypoglycaemic episodes
after bariatric surgery detected with continuous glucose monitoring (CGM) are asymp-
tomatic [162], however, data on self-reported hypoglycaemia symptoms in a general popula-
tion after RYGB and SG suggests that the prevalence of severe symptomatic hypoglycaemia
(defined as self-reported severe symptoms of hypoglycaemia in Edinburgh hypoglycaemia
scale, hypoglycaemic episodes required assistance from others, episodes of syncope, seizure
or medically confirmed hypoglycaemia) is 11.6% [164]. The incidence of hypoglycaemia
seems to be comparable between RYGB and SG [163], but RYGB is associated with more
severe hypoglycaemic episodes and symptoms [163,166]. RYGB is also associated with
higher risk of hospitalisation due to symptomatic hypoglycaemia compared to a control
population, but the actual proportion of RYGB patients presented to hospital with hypo-
glycaemia was low (0.2%) [169]. Currently, the treatment options for PHH after bariatric
surgery are limited. Patients are commonly advised to follow dietary modifications of small
and frequent meals with controlled portions of low glycaemic index carbohydrates [170].
The underlying pathophysiology of PHH after RYGB is poorly defined but several
studies have shown that after RYGB people who experience PHH have higher postprandial
peak glucose levels, higher peak insulin secretion and higher peak GLP-1 levels compared
to those without PHH [171–173]. PHH is a condition which often affects people without
T2D preoperatively and is likely to be the outcome of the altered nutrient delivery and
altered glucose absorption after RYGB rather than inherent beta-cell hypertrophy or hy-
perfunction [64,164]. Per this theory, feeding through gastrostomy tube to the remnant
stomach after RYGB or reversal of RYGB operation can lead to remission/improvement of
PHH, as well as reduction in the peak glucose, GLP-1 and insulin levels [64].
Ex-9 has been used in order to demonstrate causality between the exaggerated GLP-
1 secretion and the PHH [143,144,174]. Blockade of GLP-1 action through intravenous
Ex-9 in individuals with PHH reduced postprandial insulin secretion by around 50–
70% [143,144,175], increased the glucagon levels, increased the postprandial glucose levels
(including the nadir glucose levels) and reduced the risk and symptoms of hypogly-
caemia [143,144] (Table 3). Subjects with confirmed PHH after RYGB exhibited a greater
glycaemic response to intravenous Ex-9 administration with a pronounced increase in
postprandial glucose [144] (Table 3). In an early phase trial in people with PHH after RYGB,
subcutaneous Ex-9 increased the postprandial glucose nadir by 66%, reduced peak insulin
levels by 57%, and reduced neuroglycopenic symptoms by 80% [174] (Table 3). A phase 2
trial confirmed the safety, tolerability and efficacy of subcutaneous GLP-1 antagonist as
a treatment for PHH [176]. More specifically, twice daily administration of subcutaneous
exendin 9–39 for 3 days, effectively raised the nadir glucose levels by 39–47% and improved
by 47% the symptoms suggestive of hypoglycaemia after an oral glucose tolerance test (see
also Table 3) [176].
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Table 3. Studies using the GLP-1 antagonist Exendin 9–39 to assess glycaemic outcomes in people with type 2 diabetes or postprandial hypoglycaemia after bariatric surgery.
Author Groups No (F%) Meal Ex-9
Dose/Placebo
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Roux-en-Y gastric bypass, T2D: Type 2 Diabetes Mellitus, F: Female, MMTT: Mixed Meal Tolerance Test, SG: Sleeve Gastrectomy, PHH: Postprandial Hyperinsulinaemic Hypoglycaemia, Ex-9: Exendin 9–39, AUC:
Area Under the Curve, 2 h: 2 h, ISR: Insulin Secretion Rate, bd: twice daily, NA: Not Applicable, NR: Not Reported, ↑: increased with Ex-9 vs. placebo,↔: no change with Ex-9 vs. placebo, ↓: reduced with Ex-9 vs.
placebo,*: significant difference between surgical and non-surgical group on the outcome change with Ex-9 vs. placebo, NC: no comparison performed between study groups on the outcome change with Ex-9 vs.
placebo, ND: no difference between surgical and non-surgical group on the outcome change with Ex-9 vs. placebo, **: significant difference between surgical groups on the outcome change with Ex-9 vs. placebo, ˆ
the analysis is for a subgroup of 6 participants received ≥20 mg (≥0.35 mg/kg) of subcutaneous Lyophilized (Lyo) Ex-9, Lyo: Lyophilized Ex-9, Liq: Liquid form of Ex-9, IV: intravenous, subcut: subcutaneous.
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5. Pharmaceutical Use of Gut Hormones after Bariatric Surgery
Multiple GLP-1 receptor analogues (GLP-1 RA) are currently available for the man-
agement of obesity and T2D. The GRAVITAS (GLP-1 Receptor Agonist interVentIon for
poor responders after bariAtric Surgery) randomized controlled trial [177], demonstrated
that in individuals with persistent or recurrent T2D after RYGB or SG, use of 1.8 mg liraglu-
tide once daily in combination with lifestyle advice and support for 6 months reduced
HbA1c by 1.2% and led to an additional weight loss of 4.2 kg compared to placebo [177].
Moreover, in a recent retrospective analysis of 2092 patients, the use of liraglutide 3.0 mg
(licensed for treatment of obesity) was evaluated in patients who have had bariatric surgery
(n = 188), as well as non-surgical patients [178]. Weight loss achieved was approximately
6% after ≥ 16 weeks, which was comparable between the surgical and non-surgical groups,
confirming the potential effectiveness of liraglutide 3.0 mg after bariatric surgery [178].
Observational studies using liraglutide 3.0 mg after bariatric surgery have reported similar
results regarding weight loss [179].
These findings suggest that despite the increased endogenous postprandial GLP-1
secretion after RYGB and SG, GLP-1 RA could still be effective after bariatric surgery on
improving weight loss and glycaemic control in T2D. Currently, a number of clinical trials
with liraglutide 3.0 mg are taking place for treatment of “poor” responders to bariatric
surgery [180] or for treatment of weight regain after bariatric surgery [181].
6. Conclusions
Each bariatric procedure has a unique gut hormone profile. Changes in gut hormones
after RYGB have an important and synergistic role to increase satiety and reduce food
intake postoperatively. The best evidence currently exists for GLP-1 and PYY 3–36 to reduce
food intake after surgery. Moreover, postprandial changes in glicentin and oxyntomodulin
during the early postoperative period after RYGB and SG are associated with weight loss
outcomes. These hormones have the potential to be used as early markers of inadequate
postoperative weight loss to identify people who may require additional postoperative
supportive care.
GLP-1 contributes also to increased insulin secretion after RYGB from the early post-
operative period in people with and without T2D. GLP-1 may also be pivotal to PHH after
RYGB and ongoing studies are assessing the safety and efficacy of a subcutaneous GLP-1
receptor antagonist (Ex-9) as a treatment option. Interpretation of the role of enhanced
GLP-1 responses to improved postprandial glucose levels in people with preoperative T2D
is confounded by the effects of caloric restriction on glucose homeostasis during the early
postoperative setting and the effects of weight loss in the late postoperative setting.
Based on the described changes in gut hormones after RYGB and SG and the evidence
of their synergistic action in reducing food intake and appetite, combinations of gut
hormone receptor agonists aiming to replicate the hormonal changes after bariatric surgery
are under development and may form the next generation of treatments for obesity and
T2D [182].
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